Cargando…

Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys

OBJECTIVE: To assess the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Oman and longitudinal changes in antibody levels over time within the first 11 months of the coronavirus disease 2019 (COVID-19) pandemic. METHODS: This nationwide cross-sectional study was con...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Abri, Seif Salem, Al-Wahaibi, Adil, Al-Kindi, Hanan, Kurup, Padmamohan J, Al-Maqbali, Ali, Al-Mayahi, Zayid, Al-Tobi, Mohammed Hamed, Al-Katheri, Salim Habbash, Albusaidi, Sultan, Al-Sukaiti, Mahmood Humaid, Al Balushi, Ahmed Yar Mohammed, Abdelgadir, Iyad Omer, Al-Shehi, Nawal, Morkos, Essam, Al-Maani, Amal, Al-Rawahi, Bader, Alyaquobi, Fatma, Alqayoudhi, Abdullah, Al-Harthy, Khalid, Al-Khalili, Sulien, Al-Rashdi, Azza, Al-Shukri, Intisar, Al Ghafri, Thamra S., Al-Hashmi, Fatma, Al Jassasi, Saeed Mussalam, Alshaqsi, Nasser, Mitra, Nilanjan, Al Aamry, Humaid Suhail, Shah, Parag, Al Marbouai, Hanan Hassan, Al Araimi, Amany Hamed, Kair, Ismail Mohammed, Al Manji, Asim Mohammed, Almallak, Ahmed Said, Al Alawi, Fatma Khamis, Vaidya, Vidyanand, Muqeetullah, Muhammad, Alrashdi, Hanan, Al Jamoudi, Saud Said Nassir, Alshaqsi, Asila, Al Sharji, Abdullah, Al Shukeiri, Hamida, Al-Abri, Badr, Al-Rawahi, Sulaiman, Al-Lamki, Said H., Al-Manji, Abdulla, Al-Jardani, Amina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482550/
https://www.ncbi.nlm.nih.gov/pubmed/34601146
http://dx.doi.org/10.1016/j.ijid.2021.09.062
_version_ 1784576931021193216
author Al-Abri, Seif Salem
Al-Wahaibi, Adil
Al-Kindi, Hanan
Kurup, Padmamohan J
Al-Maqbali, Ali
Al-Mayahi, Zayid
Al-Tobi, Mohammed Hamed
Al-Katheri, Salim Habbash
Albusaidi, Sultan
Al-Sukaiti, Mahmood Humaid
Al Balushi, Ahmed Yar Mohammed
Abdelgadir, Iyad Omer
Al-Shehi, Nawal
Morkos, Essam
Al-Maani, Amal
Al-Rawahi, Bader
Alyaquobi, Fatma
Alqayoudhi, Abdullah
Al-Harthy, Khalid
Al-Khalili, Sulien
Al-Rashdi, Azza
Al-Shukri, Intisar
Al Ghafri, Thamra S.
Al-Hashmi, Fatma
Al Jassasi, Saeed Mussalam
Alshaqsi, Nasser
Mitra, Nilanjan
Al Aamry, Humaid Suhail
Shah, Parag
Al Marbouai, Hanan Hassan
Al Araimi, Amany Hamed
Kair, Ismail Mohammed
Al Manji, Asim Mohammed
Almallak, Ahmed Said
Al Alawi, Fatma Khamis
Vaidya, Vidyanand
Muqeetullah, Muhammad
Alrashdi, Hanan
Al Jamoudi, Saud Said Nassir
Alshaqsi, Asila
Al Sharji, Abdullah
Al Shukeiri, Hamida
Al-Abri, Badr
Al-Rawahi, Sulaiman
Al-Lamki, Said H.
Al-Manji, Abdulla
Al-Jardani, Amina
author_facet Al-Abri, Seif Salem
Al-Wahaibi, Adil
Al-Kindi, Hanan
Kurup, Padmamohan J
Al-Maqbali, Ali
Al-Mayahi, Zayid
Al-Tobi, Mohammed Hamed
Al-Katheri, Salim Habbash
Albusaidi, Sultan
Al-Sukaiti, Mahmood Humaid
Al Balushi, Ahmed Yar Mohammed
Abdelgadir, Iyad Omer
Al-Shehi, Nawal
Morkos, Essam
Al-Maani, Amal
Al-Rawahi, Bader
Alyaquobi, Fatma
Alqayoudhi, Abdullah
Al-Harthy, Khalid
Al-Khalili, Sulien
Al-Rashdi, Azza
Al-Shukri, Intisar
Al Ghafri, Thamra S.
Al-Hashmi, Fatma
Al Jassasi, Saeed Mussalam
Alshaqsi, Nasser
Mitra, Nilanjan
Al Aamry, Humaid Suhail
Shah, Parag
Al Marbouai, Hanan Hassan
Al Araimi, Amany Hamed
Kair, Ismail Mohammed
Al Manji, Asim Mohammed
Almallak, Ahmed Said
Al Alawi, Fatma Khamis
Vaidya, Vidyanand
Muqeetullah, Muhammad
Alrashdi, Hanan
Al Jamoudi, Saud Said Nassir
Alshaqsi, Asila
Al Sharji, Abdullah
Al Shukeiri, Hamida
Al-Abri, Badr
Al-Rawahi, Sulaiman
Al-Lamki, Said H.
Al-Manji, Abdulla
Al-Jardani, Amina
author_sort Al-Abri, Seif Salem
collection PubMed
description OBJECTIVE: To assess the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Oman and longitudinal changes in antibody levels over time within the first 11 months of the coronavirus disease 2019 (COVID-19) pandemic. METHODS: This nationwide cross-sectional study was conducted as a four-cycle serosurvey using a multi-stage stratified sampling method from July to November 2020. A questionnaire was used and included demographics, history of acute respiratory infection and list of symptoms, COVID-19 contact, previous diagnosis or admission, travel history and risk factors. RESULTS: In total, 17,457 participants were surveyed. Thirty percent were female and 66.3% were Omani. There was a significant increase in seroprevalence throughout the study cycles, from 5.5% (4.8–6.2%) in Cycle 1 to 22% (19.6–24.6%) in Cycle 4. There was no difference in seroprevalence between genders, but significant differences were found between age groups. There was a transition of seroprevalence from being higher in non-Omanis than Omanis in Cycle 1 [9.1% (7.6–10.9%) vs 3.2% (2.6–3.9%)] to being higher in Omanis than non-Omanis in Cycle 4 [24.3% (21.0–27.9%) vs 16.8% (14.9–18.9%)]. There was remarkable variation in the seroprevalence of SARS-CoV-2 according to governorate. Close contacts of people with COVID-19 had a 96% higher risk of having the disease [adjusted odds ratio (AOR) 1.96, 95% confidence intervals (CI) 1.64–2.34]. Labourers had 58% higher risk of infection compared with office workers (AOR 1.58, 95% CI 1.04–2.35). CONCLUSION: This study showed a wide variation in the spread of SARS-CoV-2 across governorates in Oman, with higher estimated seroprevalence in migrants in the first two cycles. Prevalence estimates remain low and are insufficient to provide herd immunity.
format Online
Article
Text
id pubmed-8482550
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-84825502021-09-30 Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys Al-Abri, Seif Salem Al-Wahaibi, Adil Al-Kindi, Hanan Kurup, Padmamohan J Al-Maqbali, Ali Al-Mayahi, Zayid Al-Tobi, Mohammed Hamed Al-Katheri, Salim Habbash Albusaidi, Sultan Al-Sukaiti, Mahmood Humaid Al Balushi, Ahmed Yar Mohammed Abdelgadir, Iyad Omer Al-Shehi, Nawal Morkos, Essam Al-Maani, Amal Al-Rawahi, Bader Alyaquobi, Fatma Alqayoudhi, Abdullah Al-Harthy, Khalid Al-Khalili, Sulien Al-Rashdi, Azza Al-Shukri, Intisar Al Ghafri, Thamra S. Al-Hashmi, Fatma Al Jassasi, Saeed Mussalam Alshaqsi, Nasser Mitra, Nilanjan Al Aamry, Humaid Suhail Shah, Parag Al Marbouai, Hanan Hassan Al Araimi, Amany Hamed Kair, Ismail Mohammed Al Manji, Asim Mohammed Almallak, Ahmed Said Al Alawi, Fatma Khamis Vaidya, Vidyanand Muqeetullah, Muhammad Alrashdi, Hanan Al Jamoudi, Saud Said Nassir Alshaqsi, Asila Al Sharji, Abdullah Al Shukeiri, Hamida Al-Abri, Badr Al-Rawahi, Sulaiman Al-Lamki, Said H. Al-Manji, Abdulla Al-Jardani, Amina Int J Infect Dis Article OBJECTIVE: To assess the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Oman and longitudinal changes in antibody levels over time within the first 11 months of the coronavirus disease 2019 (COVID-19) pandemic. METHODS: This nationwide cross-sectional study was conducted as a four-cycle serosurvey using a multi-stage stratified sampling method from July to November 2020. A questionnaire was used and included demographics, history of acute respiratory infection and list of symptoms, COVID-19 contact, previous diagnosis or admission, travel history and risk factors. RESULTS: In total, 17,457 participants were surveyed. Thirty percent were female and 66.3% were Omani. There was a significant increase in seroprevalence throughout the study cycles, from 5.5% (4.8–6.2%) in Cycle 1 to 22% (19.6–24.6%) in Cycle 4. There was no difference in seroprevalence between genders, but significant differences were found between age groups. There was a transition of seroprevalence from being higher in non-Omanis than Omanis in Cycle 1 [9.1% (7.6–10.9%) vs 3.2% (2.6–3.9%)] to being higher in Omanis than non-Omanis in Cycle 4 [24.3% (21.0–27.9%) vs 16.8% (14.9–18.9%)]. There was remarkable variation in the seroprevalence of SARS-CoV-2 according to governorate. Close contacts of people with COVID-19 had a 96% higher risk of having the disease [adjusted odds ratio (AOR) 1.96, 95% confidence intervals (CI) 1.64–2.34]. Labourers had 58% higher risk of infection compared with office workers (AOR 1.58, 95% CI 1.04–2.35). CONCLUSION: This study showed a wide variation in the spread of SARS-CoV-2 across governorates in Oman, with higher estimated seroprevalence in migrants in the first two cycles. Prevalence estimates remain low and are insufficient to provide herd immunity. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-11 2021-09-30 /pmc/articles/PMC8482550/ /pubmed/34601146 http://dx.doi.org/10.1016/j.ijid.2021.09.062 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Al-Abri, Seif Salem
Al-Wahaibi, Adil
Al-Kindi, Hanan
Kurup, Padmamohan J
Al-Maqbali, Ali
Al-Mayahi, Zayid
Al-Tobi, Mohammed Hamed
Al-Katheri, Salim Habbash
Albusaidi, Sultan
Al-Sukaiti, Mahmood Humaid
Al Balushi, Ahmed Yar Mohammed
Abdelgadir, Iyad Omer
Al-Shehi, Nawal
Morkos, Essam
Al-Maani, Amal
Al-Rawahi, Bader
Alyaquobi, Fatma
Alqayoudhi, Abdullah
Al-Harthy, Khalid
Al-Khalili, Sulien
Al-Rashdi, Azza
Al-Shukri, Intisar
Al Ghafri, Thamra S.
Al-Hashmi, Fatma
Al Jassasi, Saeed Mussalam
Alshaqsi, Nasser
Mitra, Nilanjan
Al Aamry, Humaid Suhail
Shah, Parag
Al Marbouai, Hanan Hassan
Al Araimi, Amany Hamed
Kair, Ismail Mohammed
Al Manji, Asim Mohammed
Almallak, Ahmed Said
Al Alawi, Fatma Khamis
Vaidya, Vidyanand
Muqeetullah, Muhammad
Alrashdi, Hanan
Al Jamoudi, Saud Said Nassir
Alshaqsi, Asila
Al Sharji, Abdullah
Al Shukeiri, Hamida
Al-Abri, Badr
Al-Rawahi, Sulaiman
Al-Lamki, Said H.
Al-Manji, Abdulla
Al-Jardani, Amina
Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys
title Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys
title_full Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys
title_fullStr Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys
title_full_unstemmed Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys
title_short Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys
title_sort seroprevalence of sars-cov-2 antibodies in the general population of oman: results from four successive nationwide sero-epidemiological surveys
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482550/
https://www.ncbi.nlm.nih.gov/pubmed/34601146
http://dx.doi.org/10.1016/j.ijid.2021.09.062
work_keys_str_mv AT alabriseifsalem seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alwahaibiadil seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alkindihanan seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT kuruppadmamohanj seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT almaqbaliali seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT almayahizayid seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT altobimohammedhamed seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alkatherisalimhabbash seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT albusaidisultan seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alsukaitimahmoodhumaid seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT albalushiahmedyarmohammed seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT abdelgadiriyadomer seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alshehinawal seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT morkosessam seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT almaaniamal seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alrawahibader seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alyaquobifatma seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alqayoudhiabdullah seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alharthykhalid seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alkhalilisulien seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alrashdiazza seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alshukriintisar seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alghafrithamras seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alhashmifatma seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT aljassasisaeedmussalam seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alshaqsinasser seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT mitranilanjan seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alaamryhumaidsuhail seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT shahparag seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT almarbouaihananhassan seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alaraimiamanyhamed seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT kairismailmohammed seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT almanjiasimmohammed seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT almallakahmedsaid seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alalawifatmakhamis seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT vaidyavidyanand seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT muqeetullahmuhammad seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alrashdihanan seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT aljamoudisaudsaidnassir seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alshaqsiasila seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alsharjiabdullah seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alshukeirihamida seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alabribadr seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT alrawahisulaiman seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT allamkisaidh seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT almanjiabdulla seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys
AT aljardaniamina seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys